Prospect: information for the user
EVENITY 105 mg injectable solution in pre-filled pen
romosozumab
Read this prospect carefully before starting to use this medicine, because it contains important information for you.
What is EVENITY
EVENITY contains the active ingredient romosozumab, a medication that contributes to strengthening bones and reducing the risk of fracture.
How is EVENITY used
EVENITY is used for the treatment of severe osteoporosis in women after menopause who have a high risk of suffering a fracture.
Osteoporosis is a disease that makes bones become fragile and brittle. Many patients with osteoporosis do not show any symptoms, but they may have a higher risk of fractures.
How EVENITY works
EVENITY is a monoclonal antibody. A monoclonal antibody is a type of protein that has been designed to recognize and bind to specific proteins in the body. EVENITY binds to a protein called sclerostin. By binding to it and blocking its activity, EVENITY:
This makes bones stronger and reduces the risk of fracture.
Do not use EVENITY
Do not use EVENITY if you are in any of the above circumstances. If you are unsure, consult your doctor or pharmacist before using EVENITY.
Warnings and precautions
Consult your doctor or pharmacist and discuss your medical history before starting to use EVENITY.
Heart attack and stroke
Heart attacks and strokes have been reported in people who receive EVENITY.
Seek medical attention immediatelyif you experience:
Your doctor will carefully evaluate the risk of cardiovascular problems before allowing you to start treatment with EVENITY. Inform your doctor if you know you have a high risk of cardiovascular problems such as established cardiovascular disease, high blood pressure, high levels of fat in the blood, diabetes, smoking, or kidney problems.
Low levels of calcium in the blood
EVENITY may cause low levels of calcium in the blood.
Inform your doctorif you notice:
Your doctor may prescribe calcium and vitamin D to help prevent low levels of calcium in the blood before you start treatment and while you are taking EVENITY. Take calcium and vitamin D as directed by your doctor. Inform your doctor if you have had severe kidney problems, kidney failure, or have needed dialysis, as this may increase your risk of having low calcium levels in the blood if you do not take calcium supplements.
Severe allergic reactions
People who use EVENITY may experience severe allergic reactions.
Seek medical attention immediatelyif you experience:
Problems in the mouth, teeth, or jaw
In rare cases (may affect up to 1 in 1000 people), patients who receive EVENITY have experienced an adverse effect called osteonecrosis of the jaw (ONJ, bone damage in the jaw). ONJ may also occur after stopping treatment. It is essential to try to prevent ONJ, as it can be a painful condition that may be difficult to treat. To reduce the risk of ONJ, you should take some precautions.
Before receiving EVENITY, inform your doctor or nurse if:
Your doctor may ask you to undergo a dental examination before starting treatment with EVENITY.
During treatment, you should maintain good oral hygiene and undergo regular dental check-ups. If you wear dentures, ensure they fit correctly. If you are receiving dental treatment or are about to undergo a dental procedure (such as a tooth extraction), inform your doctor of your dental treatment and inform your dentist that you are receiving treatment with EVENITY.
Immediately contact your doctor and dentist if you experience any problems in your mouth or teeth, such as:
Atypical femoral fractures
In rare cases, people who have used EVENITY have experienced atypical femoral fractures caused by a small or no trauma. These types of fractures often occurred after warning signs such as pain in the femur or groin for several weeks before the fracture occurred. It is unknown if EVENITY caused these unusual fractures. Inform your doctor or pharmacist if you experience any new or unusual pain in your hip, groin, or thigh.
Children and adolescents
EVENITY has not been studied in children and adolescents and is not approved for use in pediatric patients (age <18
Other medicines and EVENITY
Inform your doctor or pharmacist if you are taking, have taken recently, or may take other medicines.
Pregnancy and breastfeeding
EVENITY is expected to be used only for postmenopausal women.
Do not use EVENITY in women of childbearing age, during pregnancy, or while breastfeeding. It is unknown if EVENITY may harm the fetus or infant. Contact your doctor if you have any questions.
Driving and operating machinery
It is expected that the influence of EVENITY on the ability to drive or operate machinery will be negligible or insignificant.
EVENITY contains sodium and polysorbate 20
This medicine contains 0.070 mg of polysorbate 20 in each pre-filled syringe. Polysorbates may cause allergic reactions. Inform your doctor if you have any allergies.
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially sodium-free.
The treatment with EVENITY will be initiated and supervised by specialized doctors with experience in the treatment of osteoporosis. Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor.
Only one person with the necessary training should administer the injection.
How much to use
How to use
It is essential that you read theInstructions for useto obtain information on how to use the EVENITY pre-filled pen.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
If you use more EVENITY than you should
If you have accidentally used more EVENITY than you should, contact your doctor or pharmacist.
If you forget or cannot use EVENITY at your usual time
If you miss a dose of EVENITY, contact your doctor as soon as possible to schedule another dose. From then on, the next dose must be administered at least one month after the date of the last dose.
If you interrupt treatment with EVENITY
If you are considering interrupting treatment with EVENITY, discuss it with your doctor. Your doctor will inform you for how long you should receive treatment with EVENITY.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Discuss with your doctor the need to switch to another osteoporosis treatment after the end of your treatment with EVENITY.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Seek immediate medical attentionif you experience any of the possible symptoms ofmyocardial infarctionorstroke(rare: may affect up to 1 in 100 people) as indicated below:
Seek immediate medical attentionif you experience the following symptoms ofsevere allergic reaction(rare: may affect up to 1 in 1,000 people) as indicated below:
Inform your doctorif you observe symptoms oflow calcium levels in the blood (hypocalcemia)(rare: may affect up to 1 in 100 people) as indicated below:
Also see section 2 “What you need to know before starting to use EVENITY”.
Other side effects may include:
Very common side effects(that may affect more than 1 in 10 people):
Common side effects(that may affect up to 1 in 10 people):
Rare side effects(that may affect up to 1 in 100 people):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and on the box after “EXP/CAD”. The expiration date is the last day of the month indicated.
Store in the refrigerator (between 2 °C and 8 °C). Do not freeze.
Once you remove the preloaded pen from the refrigerator for use, do not put it back in the refrigerator, but you can keep it at room temperature (up to 25 °C) for 30 days. If not used within this period, the product must be discarded.
Keep the preloaded pen in the outer packaging to protect it from light.
Visually check the solution. Do not use the solution if it has changed color, is cloudy, or contains scales or particles.
Medicines should not be thrown away through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of EVENITY
Appearance of the product and contents of the pack
EVENITY is a clear to opalescent, colorless to yellowish injectable solution presented in a single-use pre-filled pen. The syringe inside the pen is made of plastic and has a stainless steel needle.
Pack with 2 pre-filled pens.
Multiple pack with 6 (3 packs of 2) pre-filled pens.
Only some pack sizes may be marketed.
Marketing Authorization Holder
UCB Pharma S.A.,
Allée de la Recherche 60,
B-1070 Brussels, Belgium
Manufacturer
Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder.
België/Belgique/Belgien UCB Pharma SA/NV Tél/Tel: + 32 / (0)2 559 92 00 | Lietuva UCB Pharma Oy Finland Tel: + 358 9 2514 4221 |
Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: + 32 / (0)2 559 92 00 | |
Ceská republika UCB s.r.o. Tel: + 420 221 773 411 | Magyarország UCB Magyarország Kft. Tel.: + 36-(1) 391 0060 |
Danmark UCB Nordic A/S Tlf: + 45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 36 |
Deutschland UCB Pharma GmbH Tel: + 49 /(0) 2173 48 4848 | Nederland UCB Pharma B.V. Tel.: + 31 / (0)76-573 11 40 |
Eesti UCB Pharma Oy Finland Tel: + 358 9 2514 4221 | Norge UCB Nordic A/S Tlf: + 45 / 32 46 24 00 |
Ελλ?δα UCB Α.Ε. Τηλ: + 30 / 2109974000 | Österreich UCB Pharma GmbH Tel: + 43-(0)1 291 80 00 |
España UCB Pharma, S.A. Tel: + 34 / 91 570 34 44 | Polska UCB Pharma Sp. z o.o. Tel: + 48 22 696 99 20 |
France UCB Pharma S.A. Tél: + 33 / (0)1 47 29 44 35 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: + 351 / 21 302 5300 |
Hrvatska Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | România UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 04 |
Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 | Slovenija Medis, d.o.o. Tel: + 386 1 589 69 00 |
Ísland Vistor hf. Simi: + 354 535 7000 | Slovenská republika UCB s.r.o., organizacná zložka Tel: + 421 (0) 2 5920 2020 |
Italia UCB Pharma S.p.A. Tel: + 39 / 02 300 791 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: + 358 9 2514 4221 |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: + 357 22 34 74 40 | Sverige UCB Nordic A/S Tel: + 46 / (0) 40 29 49 00 |
Latvija UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Somija) |
Date of the last revision of this leaflet: MM/AAAA.
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Go back to the page to see the usage instructions
--------------------------------------------------------------------------------------------------------------------
INSTRUCTIONS FOR USE FOR THE INJECTION OF EVENITY USING A PRE-FILLED PEN
Inject two pre-filled pens, one immediately after the other, to administer a complete dose
The instructions that follow explain how to use the pre-filled pen to inject EVENITY.
Guide to the parts: pre-filled pen
Read this before injecting the medicine. The doctor who prescribed your treatment has prescribed a dose of 210 mg per month:To receive the complete dose,two pre-filled pens with 105 mg eachmust be injected one immediately after the other. |
Step 1: Prepare
A
In these cases, use a new pre-filled pen and contact your doctor as soon as possible.
BOn a clean and well-lit work surface, place:
|
CPrepare and clean the skin where you will inject the medicine. You can choose between:
|
Step 2: Prepare
D |
|
EStretch or press the injection site to create a firm surface.
Stretch
O
Press
Step 3: Administer the injection
F |
|
G |
|
H |
|
Step 4: Dispose
I |
| |
|
Step 5: Examine the injection site
J | If there is bleeding, use a piece of cotton or gauze and press gently on the injection site for a few seconds. Do not rub the injection site. You can cover the injection site with a band-aid if necessary. |
Step 6: Repeat the process to administer the second injection and receive the complete dose
K | Repeat all the steps from Step C with the second pre-filled pen to administer the complete dose. The second injection must be administered in a different location from the first injection. If you want to use the same injection site, make sure it is not exactly the same spot. |
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.